 Located in Delaware and incorporated in mid-2014, GenPro’s mission is to accelerate the promise of precision health through the discovery and commercialization of blood-based immuno-methylome biomarkers (EpiMarkers), a new class of predictive biomarkers for: (1.) stratifying patients based on drug response, and (2.) early disease detection.

 GenPro is exclusively focused on discovering immuno-methylome EpiMarkers that change the game for biopharmaceutical companies due to their sensitive and accurate ability to phenotypically profile and characterize patients in ways that genomic markers and other techniques cannot.

 From a technology perspective, what distinguishes GenPro from all others is our proprietary, cloud-based and highly scalable analytics and machine learning platform for EpiMarker discovery from next generation sequencing data, and the translation of patentable EpiMarkers into: i) predictive, low-cost high-throughput panel assays, and ii) the illumination of valuable new molecular information on the genes, pathways, and MOI.

 From an application perspective, what distinguishes GenPro from all others is our unique ability to measure and assess from whole blood samples changes in the methylome resulting from the reaction of the circulating immune cells to the presence of different diseases and/or disease states with a high degree of accuracy, sensitivity, specificity, and stability.

 Notable is that our end-to-end platform workflow is the same for blood-based immuno-methylome EpiMarker discovery across most diseases (oncology/IO, neuro-degenerative/neuro-psychiatric, etc.) and many applications (early disease detection, responder selection into clinical trials, companion diagnostics, therapeutic effectiveness monitoring; diagnostics, etc.);

 GenPro’s go-to-market business model is driven by milestone-based collaboration partnership agreements with biopharma companies wherein GenPro provides a tailored EpiMarker-discovery-through-CDx solution matched to new drugs that significantly improve their “responder” patient selection into clinical trials thereby improving clinical trial outcomes, reducing costs, shortening time-to-market, and enhancing downstream patient care. Our near-term disease focus is oncology/immuno-oncology and neurologic diseases;

 The reaction of major biopharma companies has been very positive. This has been catalyzed by several successful EpiMarker discovery engagements over the past 9 months in four different diseases: (1) breast cancer; (2) cerebral palsy; (3) endometriosis; and (4) Lymphoma. Each involved the discovery of a unique EpiMarker and its validation via blinded samples from cohorts of 35 – 50 patients. Some were for early disease detection; the lymphoma engagement involved the discovery of an immuno-methylome EpiMarker matched to an IO-combo therapy to improve the selection of responder patients to the combo-drug into clinical trials.